Literature DB >> 17476578

Effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins.

Giuliana Silvestrini1, Paola Ballanti, Martina Leopizzi, Novella Gualtieri, Daniela Sardella, Paola Monnazzi, Simona Simeoni, Mariangela Sebastiani, Ermanno Bonucci, Francesca R Patacchioli.   

Abstract

We have studied the effects of the treatment with corticosterone (CORT), parathyroid hormone (PTH), or both (CORT + PTH), and of their withdrawal (CORT-rec and CORT + PTH-rec), on the osteoprotegerin (OPG) and receptor activator of nuclear factor-kB ligand (RANKL) localization and expression and on histomorphometric parameters in primary and secondary spongiosa of rat femur and tibia metaphyses. In the secondary spongiosa of the CORT group, the bone remodeling and the OPG/RANKL mRNA ratio decreased. In the PTH group, the bone turnover and the structural and connectivity indices increased, and the OPG/RANKL mRNA ratio fell; this ratio rose, however, in the primary spongiosa. In the CORT + PTH group, remodeling values intermediate between those of the CORT and PTH groups, were detected in the secondary spongiosa, where OPG and RANKL mRNA rose. Return towards control values was found in the recovery groups. The Cartilage Growth Plate Width was reduced in the CORT and CORT + PTH groups and returned to normal values in the recovery groups, while it was not affected by PTH. Independently of treatments, both OPG and RANKL mRNA and proteins were co-localized in the same cartilage and bone cells and in several bone marrow cells. In conclusion, the catabolic effects induced by CORT treatment occur together with an OPG fall and a RANKL rise. In the PTH group in which the bone turnover increase, the OPG and RANKL mRNA expressions differ in the primary and secondary spongiosa, confirming that the bone tissue in these sites can have different metabolic trends.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17476578     DOI: 10.1007/s10735-007-9090-9

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   3.156


  42 in total

Review 1.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

2.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

3.  Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.

Authors:  Rachel M Locklin; Sundeep Khosla; Russell T Turner; B Lawrence Riggs
Journal:  J Cell Biochem       Date:  2003-05-01       Impact factor: 4.429

4.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

Authors:  V Kartsogiannis; H Zhou; N J Horwood; R J Thomas; D K Hards; J M Quinn; P Niforas; K W Ng; T J Martin; M T Gillespie
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

5.  Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids.

Authors:  N O Vidal; H Brändström; K B Jonsson; C Ohlsson
Journal:  J Endocrinol       Date:  1998-10       Impact factor: 4.286

6.  Skeletal response to corticosteroid deficiency and excess in growing male rats.

Authors:  M Li; Y Shen; B P Halloran; B D Baumann; K Miller; T J Wronski
Journal:  Bone       Date:  1996-08       Impact factor: 4.398

7.  Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats.

Authors:  Takashi Miyazaki; Toshiyuki Matsunaga; Shuichi Miyazaki; Shigeru Hokari; Tsugikazu Komoda
Journal:  J Cell Biochem       Date:  2004-10-15       Impact factor: 4.429

Review 8.  The potential of parathyroid hormone as a therapy for osteoporosis.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Int J Fertil Womens Med       Date:  2002 May-Jun

9.  Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.

Authors:  Jay Cao; Laura Venton; Takeshi Sakata; Bernard P Halloran
Journal:  J Bone Miner Res       Date:  2003-02       Impact factor: 6.741

10.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

View more
  5 in total

1.  Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells.

Authors:  Chad M Novince; Amy J Koh; Megan N Michalski; Julie T Marchesan; Jason Wang; Younghun Jung; Janice E Berry; Matthew R Eber; Thomas J Rosol; Russell S Taichman; Laurie K McCauley
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

Review 2.  Wnt signaling: a double-edged sword in protecting bone from cancer.

Authors:  Xun Sun; Kexin Li; Bai-Yan Li; Hiroki Yokota
Journal:  J Bone Miner Metab       Date:  2022-08-30       Impact factor: 2.976

3.  OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST.

Authors:  Giuliana Silvestrini; Paola Ballanti; Mariangela Sebastiani; Martina Leopizzi; Maura Di Vito; Ermanno Bonucci
Journal:  J Mol Histol       Date:  2007-12-20       Impact factor: 2.611

4.  Effect of Restraint Stress on Plasma PTH Concentration and Its Molecular Targets Expressions in Wistar Rats.

Authors:  Sule Terzioglu-Usak; Birsen Elibol; Tugce Dalli; Cansu Guler; Erhan Aysan
Journal:  Int J Endocrinol Metab       Date:  2018-09-17

5.  Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction.

Authors:  Sébastien S Dufresne; Antoine Boulanger-Piette; Sabrina Bossé; Jérôme Frenette
Journal:  Receptors Clin Investig       Date:  2016-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.